Immunodiagnostic Systems streamlines Board

21 June 2013

Immunodiagnostic Systems streamlines Board

Immunodiagnostic Systems Holdings plc ("IDS" or "the Company" or "the Group"), a leading producer of manual and automated specialist diagnostic testing kits and instrumentation for the clinical and research markets, today announces changes to its Board structure to align the company with best practice in corporate governance.

Tony Martin, Chairman, commented, "Since July 2012, under the leadership of new CEO Patrik Dahlen, Immunodiagnostics has made significant progress in both stabilising the company and implementing a new strategy for future sustainable growth. We are today adjusting the structure of the Board in line with best corporate governance practice and to equip Immunodiagnostics for the next chapter in its evolution."

The Board has decided to move to a structure that will include only two executive directors, which will be the CEO and the Group Finance Director. The Board believes that this will provide the right balance between executive and non-executive directors for the strategic development of the Company over the short to medium term.

Accordingly, Alain Rousseau, Engineering Director, who will remain on the IDS executive team with a focus on the development and launch of the IDS-iSYS Mark II, relinquished his Board position with effect from 20 June 2013. IDS also announces that on the same day Martha Garrity, Technical Director, left the Board and IDS to pursue other opportunities. The Board's search for a successor for Martha Garrity has commenced and, Jacques de Jong, Deputy R&D Director will lead the function, under Patrik Dahlen, in the meantime.

Tony Martin, Chairman, added, "I would like to thank Martha for her important role in developing the R&D assay development capability within the Company and providing a solid technical and scientific platform for the Company to continue to grow. I also thank Alain for his contribution to the Board and look forward to the future launch of IDS-iSYS Mark II under his stewardship."

For further information:

About Immunodiagnostic Systems Holdings PLC

The Group operates in the in-vitro diagnostics ("IVD") market by designing, manufacturing and selling immunoassay kits as well as its automated analyser, the IDS-iSYS System. The IDS product range is used to measure or detect particular substances within a sample, thus aiding the diagnosis or monitoring of a disease or providing information for research studies.

http://www.idsplc.com